Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics

[1]  P. F. M. Janssen,et al.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding , 1996, Psychopharmacology.

[2]  W. Dröge,et al.  Requirement for prooxidant and antioxidant states in T cell mediated immune responses. — Relevance for the pathogenetic mechanism of AIDS? , 1991, Klinische Wochenschrift.

[3]  D. V. van Kammen,et al.  Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[4]  X. Zhang,et al.  Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements , 2003, Schizophrenia Research.

[5]  X. Zhang,et al.  Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms , 2003, Psychiatry Research.

[6]  X. Zhang,et al.  Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology , 2002, Schizophrenia Research.

[7]  L. Cao,et al.  Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study , 2001, International clinical psychopharmacology.

[8]  I. Modai,et al.  Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology , 2001, Schizophrenia Research.

[9]  M. Clerici,et al.  Cytokine profiles in drug-naive schizophrenic patients , 2001, Schizophrenia Research.

[10]  Jeffrey K. Yao,et al.  An Overview of the Evidence and Its Therapeutic Implications , 2001 .

[11]  H. Herken,et al.  Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.

[12]  Jeffrey K. Yao,et al.  Abnormal age-related changes of plasma antioxidant proteins in schizophrenia , 2000, Psychiatry Research.

[13]  Yong-Ku Kim,et al.  Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics , 2000, Schizophrenia Research.

[14]  D. Remick,et al.  Cytokines and the brain: implications for clinical psychiatry. , 2000, The American journal of psychiatry.

[15]  E. Bosmans,et al.  Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist , 2000, Schizophrenia Research.

[16]  R. Pioli,et al.  Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics , 2000, European Neuropsychopharmacology.

[17]  V. Arolt,et al.  Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment , 2000, Molecular Psychiatry.

[18]  M. Schwarz,et al.  The role of immune function in schizophrenia: an overview , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[19]  Jeffrey K. Yao,et al.  Elevated interleukin-6 in schizophrenia , 1999, Psychiatry Research.

[20]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[21]  D. Kammen,et al.  Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.

[22]  R. Pioli,et al.  The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6 , 1998, Schizophrenia Research.

[23]  S. Mukherjee,et al.  Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.

[24]  J. Reimund,et al.  Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis , 1998, European journal of clinical investigation.

[25]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. , 1997, The American journal of psychiatry.

[26]  H. Meltzer,et al.  In vivo immunomodulatory effects of clozapine in schizophrenia , 1997, Schizophrenia Research.

[27]  R. Reddy,et al.  Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  J. Laugharne,et al.  Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[29]  S. Mukherjee,et al.  Free radical pathology and antioxidant defense in schizophrenia: a review , 1996, Schizophrenia Research.

[30]  S. Mukherjee,et al.  Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.

[31]  H. Pahl,et al.  Reactive oxygen intermediates as second messengers of a general pathogen response. , 1996, Pathologie-biologie.

[32]  R. McCreadie,et al.  The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects , 1995, British Journal of Psychiatry.

[33]  C. Mcallister,et al.  Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. , 1995, The American journal of psychiatry.

[34]  Abraham Weizman,et al.  Cytokine production in drug-free and neuroleptic-treated schizophrenic patients , 1995, Biological Psychiatry.

[35]  B. Rabin,et al.  Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. , 1995, Archives of general psychiatry.

[36]  V. Pearson.  Population Policy and Eugenics in China , 1995, British Journal of Psychiatry.

[37]  G. Reynolds,et al.  Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. , 1995, Journal of psychiatric research.

[38]  J. Calabrese,et al.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. , 1995, Journal of psychiatric research.

[39]  Brown Ja,et al.  Free radical involvement in neuropsychiatric illnesses. , 1995 .

[40]  Jeffrey K. Yao,et al.  Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures , 1994, Schizophrenia Research.

[41]  H. Anisman,et al.  Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 , 1994, Brain Research.

[42]  A. Allison,et al.  Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-α, IL-β, and IL-6 by human peripheral blood mononuclear cells , 1994 .

[43]  B. Rabin,et al.  Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness , 1994, Psychiatry Research.

[44]  A. Allison,et al.  Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. , 1994, International immunology.

[45]  W. Dröge,et al.  [59] Oxidant-antioxidant status in human immunodeficiency virus infection , 1994 .

[46]  W. Dröge,et al.  Oxidant-antioxidant status in human immunodeficiency virus infection. , 1994, Methods in enzymology.

[47]  J. Krystal,et al.  Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. , 1993, The American journal of psychiatry.

[48]  Jeffrey K. Yao,et al.  Red blood cell membrane dynamics in schizophrenia , 1993, Schizophrenia Research.

[49]  J. Lohr,et al.  Smoking and schizophrenia , 1992, Schizophrenia Research.

[50]  P. Lapchak.  A role for interleukin‐2 in the regulation of striatal dopaminergic function , 1992, Neuroreport.

[51]  K. Albermann,et al.  Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review) , 1992 .

[52]  J. Lohr.  Oxygen radicals and neuropsychiatric illness. Some speculations. , 1991, Archives of general psychiatry.

[53]  D. Horrobin,et al.  Fatty acid levels in the brains of schizophrenics and normal controls , 1991, Biological Psychiatry.

[54]  S. Mukherjee,et al.  Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.

[55]  P. Baeuerle,et al.  Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. , 1991, The EMBO journal.

[56]  D. Jeste,et al.  Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia , 1990, Biological Psychiatry.

[57]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[58]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[59]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.